Irbesartan 75 mg, 150, 300 mg Tablets TajP harma : Uses, Side E ffects, I nteractions, Pict ures, War nings, Irbesartan Dosage & Rx Info | Irbesartan Us es, Side E ffe cts - Antihy pertensive, Irbesartan : Indications, Side E ffe cts, War nings, Irbe sartan - Dr ug Information - TajP harma, Ir besartan dose Taj pharma ceu ticals Irbesartan intera ctions, Taj Phar mace utical Irbesartan contraindicati ons, Irbesartan pri ce, Irbesarta nTajPhar ma ant ipsy choti cs I miprami n Tablets S mPC - TajPhar ma Stay connecte d to all update d on Ir besartanTaj P harma ceuti cals Taj phar maceuticals Hy derabad. Patient Infor mation Leaflets, S mPC.
Irbesartan tablets USP 75mg/150mg/300mg 1. Name of the medicinal product Irbesartan 75mg tablets USP Taj Pharma Irbesartan 150mg tablets USP Taj Pharma Irbesartan 300mg tablets USP Taj Pharma
2. Qualitative and quantitative composition a) Each uncoated tablet contains: Irbesartan USP 75mg Excipients q.s. b) Each uncoated tablet contains: Irbesartan USP 150mg Excipients q.s. c) Each uncoated tablet contains: Irbesartan USP 300mg Excipients q.s. For the full list of excipients, see section 6.1.
3. Pharmaceutical form Tablet
4. Clinical particulars 4.1 Therapeutic indications Irbesartan is indicated in adults for the treatment of essential hypertension. It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).
4.2 Posology and method of administration Posology The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Irbesartan at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan can be increased to 300 mg, or other antihypertensive agents can be added. In particular, the addition of a diuretic such as
hydrochlorothiazide has been shown to have an additive effect with Irbesartan (see sections 4.3, 4.4, 4.5 and 5.1). In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. The demonstration of renal benefit of Irbesartan in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). Special Populations Renal impairment: no dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). Hepatic impairment: no dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment. Older people: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly. Paediatric population: the safety and efficacy of irbesartan in children aged 0 to 18 has not been established. Currently available data are described in section 4.8, 5.1 and 5.2, but not recommendation on a posology can be made. Method of administration For oral use.
4.3 Contraindications Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1. Second and third trimesters of pregnancy (see sections 4.4 and 4.6). The concomitant use of Irbesartan with aliskirencontaining products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
4.4 Special warnings and precautions for use Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Irbesartan.